Frontiers in Immunology (Sep 2022)
Circulating pyruvate is a potent prognostic marker for critical COVID-19 outcomes
- Victòria Ceperuelo-Mallafré,
- Victòria Ceperuelo-Mallafré,
- Victòria Ceperuelo-Mallafré,
- Laia Reverté,
- Laia Reverté,
- Joaquim Peraire,
- Joaquim Peraire,
- Joaquim Peraire,
- Joaquim Peraire,
- Ana Madeira,
- Ana Madeira,
- Elsa Maymó-Masip,
- Elsa Maymó-Masip,
- Miguel López-Dupla,
- Miguel López-Dupla,
- Miguel López-Dupla,
- Miguel López-Dupla,
- Alicia Gutierrez-Valencia,
- Ezequiel Ruiz-Mateos,
- Maria José Buzón,
- Rosa Jorba,
- Rosa Jorba,
- Rosa Jorba,
- Joan Vendrell,
- Joan Vendrell,
- Joan Vendrell,
- Joan Vendrell,
- Teresa Auguet,
- Teresa Auguet,
- Teresa Auguet,
- Montserrat Olona,
- Montserrat Olona,
- Montserrat Olona,
- Montserrat Olona,
- Francesc Vidal,
- Francesc Vidal,
- Francesc Vidal,
- Francesc Vidal,
- Anna Rull,
- Anna Rull,
- Anna Rull,
- Anna Rull,
- Sonia Fernández-Veledo,
- Sonia Fernández-Veledo
Affiliations
- Victòria Ceperuelo-Mallafré
- Universitat Rovira i Virgili (URV), Tarragona, Spain
- Victòria Ceperuelo-Mallafré
- Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain
- Victòria Ceperuelo-Mallafré
- CIBER de Diabetes y Enfermedades Metaboílicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III, Madrid, Spain
- Laia Reverté
- Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain
- Laia Reverté
- CIBER Enfermedades Infecciosas (CIBERINFEC)-Instituto de Salud Carlos III, Madrid, Spain
- Joaquim Peraire
- Universitat Rovira i Virgili (URV), Tarragona, Spain
- Joaquim Peraire
- Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain
- Joaquim Peraire
- CIBER Enfermedades Infecciosas (CIBERINFEC)-Instituto de Salud Carlos III, Madrid, Spain
- Joaquim Peraire
- Hospital Universitari de Tarragona Joan XXIII (HJ23), Tarragona, Spain
- Ana Madeira
- Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain
- Ana Madeira
- CIBER de Diabetes y Enfermedades Metaboílicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III, Madrid, Spain
- Elsa Maymó-Masip
- Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain
- Elsa Maymó-Masip
- CIBER de Diabetes y Enfermedades Metaboílicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III, Madrid, Spain
- Miguel López-Dupla
- Universitat Rovira i Virgili (URV), Tarragona, Spain
- Miguel López-Dupla
- Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain
- Miguel López-Dupla
- CIBER Enfermedades Infecciosas (CIBERINFEC)-Instituto de Salud Carlos III, Madrid, Spain
- Miguel López-Dupla
- Hospital Universitari de Tarragona Joan XXIII (HJ23), Tarragona, Spain
- Alicia Gutierrez-Valencia
- Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital, Consejo Superior de Investigaciones Científicas (CSIC), University of Seville, Seville, Spain
- Ezequiel Ruiz-Mateos
- Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital, Consejo Superior de Investigaciones Científicas (CSIC), University of Seville, Seville, Spain
- Maria José Buzón
- Infectious Diseases Department, Vall d’Hebron Institute of Research (VHIR), Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, (VHIR) Task Force COVID-19, Barcelona, Spain
- Rosa Jorba
- Universitat Rovira i Virgili (URV), Tarragona, Spain
- Rosa Jorba
- Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain
- Rosa Jorba
- Hospital Universitari de Tarragona Joan XXIII (HJ23), Tarragona, Spain
- Joan Vendrell
- Universitat Rovira i Virgili (URV), Tarragona, Spain
- Joan Vendrell
- Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain
- Joan Vendrell
- CIBER de Diabetes y Enfermedades Metaboílicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III, Madrid, Spain
- Joan Vendrell
- Hospital Universitari de Tarragona Joan XXIII (HJ23), Tarragona, Spain
- Teresa Auguet
- Universitat Rovira i Virgili (URV), Tarragona, Spain
- Teresa Auguet
- Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain
- Teresa Auguet
- Hospital Universitari de Tarragona Joan XXIII (HJ23), Tarragona, Spain
- Montserrat Olona
- Universitat Rovira i Virgili (URV), Tarragona, Spain
- Montserrat Olona
- Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain
- Montserrat Olona
- CIBER Enfermedades Infecciosas (CIBERINFEC)-Instituto de Salud Carlos III, Madrid, Spain
- Montserrat Olona
- Hospital Universitari de Tarragona Joan XXIII (HJ23), Tarragona, Spain
- Francesc Vidal
- Universitat Rovira i Virgili (URV), Tarragona, Spain
- Francesc Vidal
- Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain
- Francesc Vidal
- CIBER Enfermedades Infecciosas (CIBERINFEC)-Instituto de Salud Carlos III, Madrid, Spain
- Francesc Vidal
- Hospital Universitari de Tarragona Joan XXIII (HJ23), Tarragona, Spain
- Anna Rull
- Universitat Rovira i Virgili (URV), Tarragona, Spain
- Anna Rull
- Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain
- Anna Rull
- CIBER Enfermedades Infecciosas (CIBERINFEC)-Instituto de Salud Carlos III, Madrid, Spain
- Anna Rull
- Hospital Universitari de Tarragona Joan XXIII (HJ23), Tarragona, Spain
- Sonia Fernández-Veledo
- Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain
- Sonia Fernández-Veledo
- CIBER de Diabetes y Enfermedades Metaboílicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III, Madrid, Spain
- DOI
- https://doi.org/10.3389/fimmu.2022.912579
- Journal volume & issue
-
Vol. 13
Abstract
BackgroundCoronavirus-19 (COVID-19) disease is driven by an unchecked immune response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus which alters host mitochondrial-associated mechanisms. Compromised mitochondrial health results in abnormal reprogramming of glucose metabolism, which can disrupt extracellular signalling. We hypothesized that examining mitochondrial energy-related signalling metabolites implicated in host immune response to SARS-CoV-2 infection would provide potential biomarkers for predicting the risk of severe COVID-19 illness.MethodsWe used a semi-targeted serum metabolomics approach in 273 patients with different severity grades of COVID-19 recruited at the acute phase of the infection to determine the relative abundance of tricarboxylic acid (Krebs) cycle-related metabolites with known extracellular signaling properties (pyruvate, lactate, succinate and α-ketoglutarate). Abundance levels of energy-related metabolites were evaluated in a validation cohort (n=398) using quantitative fluorimetric assays.ResultsIncreased levels of four energy-related metabolites (pyruvate, lactate, a-ketoglutarate and succinate) were found in critically ill COVID-19 patients using semi-targeted and targeted approaches (p<0.05). The combined strategy proposed herein enabled us to establish that circulating pyruvate levels (p<0.001) together with body mass index (p=0.025), C-reactive protein (p=0.039), D-Dimer (p<0.001) and creatinine (p=0.043) levels, are independent predictors of critical COVID-19. Furthermore, classification and regression tree (CART) analysis provided a cut-off value of pyruvate in serum (24.54 µM; p<0.001) as an early criterion to accurately classify patients with critical outcomes.ConclusionOur findings support the link between COVID-19 pathogenesis and immunometabolic dysregulation, and show that fluorometric quantification of circulating pyruvate is a cost-effective clinical decision support tool to improve patient stratification and prognosis prediction.
Keywords